Trump CDC nominee Schwartz vows to divest holdings, resign board roles

Erica Schwartz is promising to cut the financial and corporate ties that could shadow her rise to the nation’s top public-health job. In a June 16 ethics disclosure, President Donald Trump’s nominee to lead the Centers for Disease Control and Prevention said she will resign from UnitedHealth, leave board positions, sell health-care related holdings and step aside from matters involving former employers and clients if she is confirmed.

The agreement reaches beyond paper compliance. It places the nominee’s private-sector interests under a bright light at an agency whose director helps steer disease surveillance, outbreak response, vaccine policy and coordination with state and local health systems. Schwartz also said she would receive a cash payment equal to one year’s salary and a bonus before taking the post, or forfeit that compensation if required, underscoring how consequential the transition will be for both her finances and the public’s confidence in the job.

Trump nominated Schwartz on April 16, and the Senate Committee on Health, Education, Labor and Pensions listed her nomination on April 21 to replace Susan Monarez. Schwartz, a former deputy surgeon general during the COVID-19 pandemic and a retired rear admiral in the U.S. Public Health Service Commissioned Corps, has been cast as a more traditional establishment pick than a figure associated with the Make America Healthy Again movement. If confirmed, she would become the CDC’s fourth leader in roughly a year, a level of turnover that has left the agency under intense scrutiny in Washington and Atlanta.

That backdrop makes her ethics pledge more than a routine personnel filing. Financial disclosures are standard for senior nominees, especially when they come from sectors touched by federal policy, but the CDC director sits at the center of decisions that can affect insurers, providers and other health-care clients. Schwartz’s promise to sell health-care holdings and recuse herself from former business relationships is meant to address those conflicts before they reach the agency’s scientific work.

Public-health reaction to Schwartz has been mixed, but generally warmer than the response to some earlier CDC choices. Some observers have described “cautious optimism,” pointing to her scientific credentials and the absence of public ties to the anti-vaccine movement. Others have called her deeply credentialed and supportive of vaccines, while warning that the larger threat to CDC credibility comes from the administration’s broader vaccine-policy moves and shifts in the advisory process. For now, Schwartz’s disclosure is both a reassurance and a warning: the ethics cleanup looks familiar, but the scale of the conflicts shows how much trust the next CDC director will need to rebuild.